AMG 224: This phase I trial is evaluating the drug AMG 224 as a treatment for Multiple Myeloma in patients who have relapsedA Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma

Inclusion

- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma.

Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide).

• Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).
• Measurable disease per the International Myeloma Working Group (IMWG) response criteria
• Hematological function, as follows, without transfusion support:
• Absolute neutrophil count ≥ 1.0 X 10^9/L,
• Platelet count ≥ 75 X 10^9/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 10^9/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support
• Hemoglobin > 8 g/dL (> 80 g/L)
• Adequate renal and hepatic function
• Left ventricular ejection fraction (LVEF) > 50%